Rockland, Inc. acquires Epi-Plus product line from 21st Century Biochemicals
Apr 10, 2013
Rockland now manufactures antibodies from the Epi-Plus® epigenetics line that can assist in various types of cancer research. Epigenetic alterations are extremely important to a cell’s transformation to cancer, and the mechanisms of epigenetic silencing of tumor suppressor genes and activation of oncogenes holds great promise for cancer prevention, detection, and therapy. Rockland epigenetic antibodies are developed under the most stringent of quality standards to ensure repeatable, accurate results.
More information on the acquisition can be found here.
To find out more about Rockland’s complete list of Epigenetics antibodies please visit www.rockland-inc.com/epigenetic_antibodies.aspx.